Liver-expressed antimicrobial peptide 2 is a hepatokine regulated by ghrelin, nutrients, and body weight.
Diabetes
Ghrelin
Hepatokine
LEAP2
Obesity
Vertical sleeve gastrectomy
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
21 Oct 2024
21 Oct 2024
Historique:
received:
22
03
2024
accepted:
23
09
2024
medline:
22
10
2024
pubmed:
22
10
2024
entrez:
21
10
2024
Statut:
epublish
Résumé
Liver-expressed antimicrobial peptide 2 (LEAP2) is a peptide that counteracts the hunger hormone ghrelin-induced functions. Recently, we showed that vertical sleeve gastrectomy (VSG) did not alter the serum LEAP2 concentration in individuals with obesity. Here, we investigated the effects of VSG in both chow diet (CD)-fed and high-fat diet (HFD)-fed mice. In CD-fed mice, VSG increased plasma LEAP2 levels and hepatic Leap2 mRNA levels while decreasing body weight, blood glucose levels, and ghrelin levels. Intraperitoneal (ip) administration of ghrelin reversed these changes. These effects were found in both male and female mice. In contrast, VSG or weight loss in HFD-induced obese mice decreased LEAP2 levels. After fasting, the plasma LEAP2 concentration was in the following order: hepatic vein > abdominal aorta > portal vein. A high glucose concentration robustly increased the plasma LEAP2 concentration in the hepatic vein and abdominal aorta but not in the portal vein. In addition, corn oil or palmitate increased LEAP2 expression and secretion. The increase in LEAP2 levels after the meal tolerance test was delayed in the human subjects with diabetes. Our data suggest that various factors (metabolic, hormonal, and nutritional) regulate LEAP2, and the liver is the predominant site for the production and secretion of LEAP2. Furthermore, the interaction between ghrelin and LEAP2 is involved in the pathogenesis of obesity and diabetes.
Identifiants
pubmed: 39433849
doi: 10.1038/s41598-024-74048-6
pii: 10.1038/s41598-024-74048-6
doi:
Substances chimiques
Ghrelin
0
liver-expressed antimicrobial peptide 2, human
0
Antimicrobial Cationic Peptides
0
Blood Glucose
0
Blood Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
24782Informations de copyright
© 2024. The Author(s).
Références
Kojima, M. et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 402, 656–660 (1999).
doi: 10.1038/45230
pubmed: 10604470
Nakazato, M. et al. A role for ghrelin in the central regulation of feeding. Nature. 409, 194–198 (2001).
doi: 10.1038/35051587
pubmed: 11196643
Yanagi, S., Sato, T., Kangawa, K. & Nakazato, M. The homeostatic force of ghrelin. Cell. Metab. 27, 786–804 (2018).
doi: 10.1016/j.cmet.2018.02.008
pubmed: 29576534
Krause, A. et al. Isolation and biochemical characterization of LEAP-2, a novel blood peptide expressed in the liver. Protein Sci. 12, 143–152 (2003).
doi: 10.1110/ps.0213603
pubmed: 12493837
pmcid: 2312392
Krause, A. et al. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett. 480, 147–150 (2000).
doi: 10.1016/S0014-5793(00)01920-7
pubmed: 11034317
Ge, X. et al. LEAP2 is an endogenous antagonist of the ghrelin receptor. Cell. Metab. 27, 461–469 (2018).
doi: 10.1016/j.cmet.2017.10.016
pubmed: 29233536
Islam, M. N. et al. Liver-expressed antimicrobial peptide 2 antagonizes the effect of ghrelin in rodents. J. Endocrinol. 244, 13–23 (2020).
doi: 10.1530/JOE-19-0102
pubmed: 31539874
Islam, M. N. et al. Liver-expressed antimicrobial peptide 2 functions independently of growth hormone secretagogue receptor in calorie-restricted mice. Peptides. 151, 170763 (2022).
doi: 10.1016/j.peptides.2022.170763
pubmed: 35151767
Hagemann, C. A. et al. LEAP2 reduces postprandial glucose excursions and ad libitum food intake in healthy men. Cell. Rep. Med. 3, 100582 (2022).
doi: 10.1016/j.xcrm.2022.100582
pubmed: 35492241
pmcid: 9043997
Mani, B. K. et al. LEAP2 changes with body mass and food intake in humans and mice. J. Clin. Invest. 129, 3909–3923 (2019).
doi: 10.1172/JCI125332
pubmed: 31424424
pmcid: 6715358
Cummings, B. P. et al. Vertical sleeve gastrectomy improves glucose and lipid metabolism and delays diabetes onset in UCD-T2DM rats. Endocrinology. 153, 3620–3632 (2012).
doi: 10.1210/en.2012-1131
pubmed: 22719048
pmcid: 3404344
Noda, T. et al. Concurrent use of teneligliptin and canagliflozin improves glycemic control with beneficial effects on plasma glucagon and glucagon-like peptide-1: a single-arm study. Diabetes Ther. 10, 1835–1846 (2019).
doi: 10.1007/s13300-019-0666-7
pubmed: 31300948
pmcid: 6778556
Sakai, K. et al. Human liver-expressed antimicrobial peptide 2 elevation in the cerebrospinal fluid in bacterial meningitis. Brain Behav. 11, e02111 (2021).
doi: 10.1002/brb3.2111
pubmed: 33811478
pmcid: 8119843
Nabekura, H. et al. Liver-expressed antimicrobial peptide 2 is a hepatokine that predicts weight loss and complete remission of type 2 diabetes mellitus after vertical sleeve gastrectomy in Japanese individuals. Obes. Facts. 16, 392–400 (2023).
doi: 10.1159/000530733
pubmed: 37094564
pmcid: 10427959
Zhang, W. et al. Neuromedin U uses Gαi2 and Gαo to suppress glucose-stimulated Ca2
doi: 10.1371/journal.pone.0250232
pubmed: 33857254
pmcid: 8049253
Bate, T. S. R., Gadd, V. L., Forbes, S. J. & Callanan, A. Response differences of HepG2 and primary, mouse hepatocytes to morphological changes in Electrospun PCL scaffolds. Sci. Rep. 11, 3059 (2021).
doi: 10.1038/s41598-021-81761-z
pubmed: 33542251
pmcid: 7862353
Pedersen, M. G. B. et al. Nutrient sensing: LEAP2 concentration in response to fasting, glucose, lactate, and β-hydroxybutyrate in healthy young males. Am. J. Clin. Nutr. 118, 1091–1098 (2023).
doi: 10.1016/j.ajcnut.2023.10.007
pubmed: 37844838
Gradel, A. K. J. et al. The dietary regulation of LEAP2 depends on meal composition in mice. FASEB J. 37, e22923 (2023).
doi: 10.1096/fj.202201828R
pubmed: 37104087
Yue, F. et al. Mouse ENCODE consortium. A comparative encyclopedia of DNA elements in the mouse genome. Nature. 20, 355–364 (2014).
doi: 10.1038/nature13992
Fagerberg, L. et al. Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. Mol. Cell. Proteom. 13, 397–406 (2014).
doi: 10.1074/mcp.M113.035600
Roebroek, A. J. M. et al. Limited redundancy of the proprotein convertase furin in mouse liver. J. Biol. Chem. 279, 53442–53450 (2004).
doi: 10.1074/jbc.M407152200
pubmed: 15471862
Naznin, F. et al. Restoration of metabolic inflammation-related ghrelin resistance by weight loss. J. Mol. Endocrinol. 60, 109–118 (2018).
doi: 10.1530/JME-17-0192
pubmed: 29233861
Briggs, D. I., Enriori, P. J., Lemus, M. B., Cowley, M. A. & Andrews, Z. B. Diet-induced obesity causes ghrelin resistance in arcuate NPY/AgRP neurons. Endocrinology. 151, 4745–4755 (2010).
doi: 10.1210/en.2010-0556
pubmed: 20826561
Sekiguchi, M., Oda, I., Matsuda, T. & Saito, Y. Epidemiological trends and future perspectives of gastric cancer in eastern asia. Digestion. 103, 22–28 (2022).
doi: 10.1159/000518483
pubmed: 34515086
Zhuang, C. L. et al. Cachexia versus Sarcopenia in clinical characteristics and prognostic value after radical gastrectomy for gastric cancer: A large-scale prospective study. Ann. Surg. Oncol. 29, 2348–2358 (2022).
doi: 10.1245/s10434-021-11084-w
pubmed: 34797480
Shiomi, Y. et al. Z-505, an oral ghrelin receptor agonist, attenuates anorexia after total gastrectomy in rats. J. Surg. Res. 246, 527–534 (2020).
doi: 10.1016/j.jss.2019.09.035
pubmed: 31668932
St-Pierre, D. H. et al. Relationship between ghrelin and energy expenditure in healthy young women. J. Clin. Endocrinol. Metab. 89, 5993–5997 (2004).
doi: 10.1210/jc.2004-0613
pubmed: 15579749
Müller, A., Berkmann, J. C., Scheerer, P., Biebermann, H. & Kleinau, G. Insights into basal signaling regulation, oligomerization, and structural organization of the human G-protein coupled receptor 83. PLoS One. 11, e0168260 (2016).
doi: 10.1371/journal.pone.0168260
pubmed: 27936173
pmcid: 5148169